Eli Lilly price target lowered to $1,190 from $1,250 at Citi

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and pharmaceuticals coverage. Higher-growth names like Eli Lilly (LLY) and Vertex VRTX) remain Citi’s favorites in the group, given their “strong demand” in key franchises and a lower impact from potential policy changes. The sector “looks tricky” in 2025 given negative sentiment, but growth expectations appear beatable with a focus on commercial execution, the analyst tells investors in a research note.